Success Metrics

Clinical Success Rate
100.0%

Based on 24 completed trials

Completion Rate
100%(24/24)
Active Trials
1(3%)
Results Posted
29%(7 trials)

Phase Distribution

Ph phase_3
6
21%
Ph phase_4
5
17%
Ph not_applicable
1
3%
Ph phase_1
14
48%
Ph phase_2
3
10%

Phase Distribution

14

Early Stage

3

Mid Stage

11

Late Stage

Phase Distribution29 total trials
Phase 1Safety & dosage
14(48.3%)
Phase 2Efficacy & side effects
3(10.3%)
Phase 3Large-scale testing
6(20.7%)
Phase 4Post-market surveillance
5(17.2%)
N/ANon-phased studies
1(3.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

24 of 28 finished

Non-Completion Rate

14.3%

4 ended early

Currently Active

1

trials recruiting

Total Trials

29

all time

Status Distribution
Active(1)
Completed(24)
Terminated(4)

Detailed Status

Completed24
Withdrawn4
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 114 (48.3%)
Phase 23 (10.3%)
Phase 36 (20.7%)
Phase 45 (17.2%)
N/A1 (3.4%)

Trials by Status

withdrawn414%
completed2483%
recruiting13%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT03919292Phase 1

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Recruiting
NCT00211757Phase 2

Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism

Completed
NCT03012815Phase 4

Gabapentin for Alcohol Withdrawal Syndrome

Completed
NCT01760785Not Applicable

Valproate for Mood Swings and Alcohol Use Following Head Injury

Completed
NCT00218114Phase 3

Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults

Completed
NCT01170325Phase 2

A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG

Withdrawn
NCT00864006Phase 1

Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions

Completed
NCT02094651Phase 2

Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium

Withdrawn
NCT02166229Phase 1

Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma

Withdrawn
NCT00287053Phase 4

Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation

Completed
NCT00176202Phase 3

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

Completed
NCT00228046Phase 4

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

Completed
NCT01587066Phase 4

Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression

Withdrawn
NCT01581775Phase 1

Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions

Completed
NCT01581788Phase 1

Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed Conditions

Completed
NCT01132196Phase 1

Bioequivalence Study of Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Under Fed Conditions

Completed
NCT01132170Phase 1

Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting Conditions

Completed
NCT01132183Phase 1

Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Apple Sauce)

Completed
NCT01055938Phase 1

Bioequivalence Study of Dr. Reddy's Divalproex Sodium Capsules (Sprinkle), 125 mg Under Fasting Conditions

Completed
NCT01056627Phase 1

Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed Condition

Completed

Drug Details

Intervention Type
DRUG
Total Trials
29